Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/β2-catenin pathway

Current Opinion in Hematology

Volumn 19, Issue 4, 2012, Pages 280-286

  Fung, Tsz K ^a   Gandillet, Arnaud ^a,b   So, Chi W E ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

glycogen synthase kinase 3; Hox; leukemic stem cells; mixed lineage leukemia; Wnt catenin

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3; HOX PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER STEM CELL; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; DEREGULATION; DRUG TARGETING; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA; LEUKEMIA STEM CELL; LYMPHOCYTE ACTIVATION; MIXED LINEAGE LEUKEMIA; MOLECULAR MECHANICS; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LEUKEMIA, BIPHENOTYPIC, ACUTE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84862137376     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283545615     Document Type: Review

References (57)

1. So CW, Karsunky H, Passegue E, et al. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell 2003; 3:161-171. (Pubitemid 37443388)
2. Cozzio A, Passegue E, Ayton PM, et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17:3029-3035. (Pubitemid 38040767)
3. Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6:587-596. (Pubitemid 40017702)
4. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116:354-365.
5. Nguyen LV, Vanner R, Dirks P, et al. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012; 12:133-143.
6. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007; 7:823-833. (Pubitemid 350006257)
7. So CW, Cleary ML. Dimerization: a versatile switch for oncogenesis. Blood 2004; 104:919-922. (Pubitemid 39038008)
8. Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005; 121:167-178. (Pubitemid 40546386)
9. Cheung N, Chan LC, Thompson A, et al. Protein arginine- methyltransferasedependent oncogenesis. Nat Cell Biol 2007; 9:1208-1215.
10. Cheung N, So CW. Transcriptional and epigenetic networks in haematological malignancy. FEBS Lett 2011; 585:2100-2111.
11. Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478:529-533.
12. Tan J, Jones M, Koseki H, et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell 2011; 20:563-575.
13. Faber J, Krivtsov AV, Stubbs MC, et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009; 113:2375-2385.
14. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003; 17:2298-2307. (Pubitemid 37128644)
15. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286:531-537.
16. Kroon E, Krosl J, Thorsteinsdottir U, et al. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 1998; 17:3714-3725. (Pubitemid 28327389)
17. Gough SM, Slape CI, Aplan PD. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood 2011; 118:6247-6257.
18. Shakoori A, Ougolkov A, Yu ZW, et al. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 2005; 334:1365-1373. (Pubitemid 41074725)
19. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, et al. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005; 65:2076-2081. (Pubitemid 40490111)
20. Wang Z, Iwasaki M, Ficara F, et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 2010; 17:597-608.
21. Wang Z, Smith KS, Murphy M, et al. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008; 455:1205-1209.
22. Holmes T, O'Brien TA, Knight R, et al. Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells 2008; 26:1288-1297.
23. Song EY, Palladinetti P, Klamer G, et al. Glycogen synthase kinase-3beta inhibitors suppress leukemia cell growth. Exp Hematol 2010; 38:908-921; e901.
24. Banerji V, FrummSM, Ross KN, et al. The intersection of genetic and chemical genomic screens identifies GSK-3alpha as a target in human acute myeloid leukemia. J Clin Invest 2012; 122:935-947.
25. Trowbridge JJ, Xenocostas A, Moon RT, et al. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med 2006; 12:89-98. (Pubitemid 43050082)
26. Kitagawa M, Hatakeyama S, Shirane M, et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J 1999; 18:2401-2410. (Pubitemid 29213274)
27. Farago M, Dominguez I, Landesman-Bollag E, et al. Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res 2005; 65:5792-5801. (Pubitemid 40911183)
28. Ma C, Wang J, Gao Y, et al. The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. Cancer Res 2007; 67:7756-7764. (Pubitemid 47281369)
29. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351:657-667. (Pubitemid 39063268)
30. Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12:528-541. (Pubitemid 350199070)
31. Yeung J, Esposito MT, Gandillet A, et al. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010; 18:606-618.
32. Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327:1650-1653.
33. Ysebaert L, Chicanne G, Demur C, et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 2006; 20:1211-1216. (Pubitemid 43905823)
34. Chen CC, Gau JP, You JY, et al. Prognostic significance of beta-catenin and topoisomerase IIalpha in de novo acute myeloid leukemia. Am J Hematol 2009; 84:87-92.
35. Gandillet A, Park S, Lassailly F, et al. Heterogeneous sensitivity of human acute myeloid leukemia to beta-catenin down-modulation. Leukemia 2011; 25:770-780.
36. Siapati EK, Papadaki M, Kozaou Z, et al. Proliferation and bone marrow engraftment of AML blasts is dependent on beta-catenin signalling. Br J Haematol 2011; 152:164-174.
37. Hu Y, Chen Y, Douglas L, et al. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABLinduced chronic myeloid leukemia. Leukemia 2009; 23:109-116.
38. Nguyen DX, Chiang AC, Zhang XH, et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009; 138:51-62.
39. Jeannet G, Scheller M, Scarpellino L, et al. Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. Blood 2008; 111:142-149.
40. Cobas M, Wilson A, Ernst B, et al. Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. J Exp Med 2004; 199:221-229.
41. Chikazawa N, Tanaka H, Tasaka T, et al. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res 2010; 30:2041-2048.
42. Cui J, Jiang W, Wang S, et al. Role of Wnt/beta-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des 2012; 18:2464-2471.
43. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nature reviews. Drug Discov 2006; 5:997-1014. (Pubitemid 44835127)
44. Song S, Christova T, Perusini S, et al. Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers. Cancer Res 2011; 71: 7628-7639.
45. Fung TK, Leung AY, So CW. Stem cells and cancer stem cells. 1st ed. In: Hayat MA, editor. The Wnt/beta-catenin pathway as a potential target for drug resistant leukemic stem cells. Springer (in press).
46. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469:356-361.
47. Li L, Wang L, Wang Z, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012; 21:266-281.
48. Yuan H, Wang Z, Li L, et al. Activation of stress response gene SIRT1 by BCRABL promotes leukemogenesis. Blood 2012; 119:1904-1914.
49. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011; 20:53-65.
50. Smith LL, Yeung J, Zeisig BB, et al. Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic Stem Cells. Cell stem cell 2011; 8:649-662.
51. Yuan J, Takeuchi M, Negishi M, et al. Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells. Leukemia 2011; 25:1335-1343.
52. Dierks C, Beigi R,GuoGR, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008; 14:238-249.
53. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009; 458:776-779.
54. Guo W, Schubbert S, Chen JY, et al. Suppression of leukemia development caused by PTEN loss. Proc Natl Acad Sci USA 2011; 108:1409-1414.
55. Espinosa L, Cathelin S, D'Altri T, et al. The Notch/Hes1 pathway sustains NFkappaB activation through CYLD repression in T cell leukemia. Cancer Cell 2010; 18:268-281.
56. Klinakis A, Lobry C, Abdel-Wahab O, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011; 473: 230-233.
57. Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441: 475-482. (Pubitemid 44050144)